Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN95588307
ISRCTN95588307
Completed
未知

Response to routine immunisations in human immunodeficiency virus (HIV) infected adults: a cross-sectional cohort study

niversity of Birmingham (UK)0 sites1,115 target enrollmentMarch 10, 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Birmingham (UK)
Enrollment
1115
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 10, 2011
End Date
TBD
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
niversity of Birmingham (UK)

Eligibility Criteria

Inclusion Criteria

  • •1\. Aged over 18 years old, either sex
  • •2\. Informed consent given
  • •3\. Participant cases: proven HIV infection
  • •4\. Participant controls: proven absence of HIV\-infection

Exclusion Criteria

  • •1\. Under 18 years of age
  • •2\. Informed consent withheld
  • •3\. HIV\-status unknown

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VACThe vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.MedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisMedDRA version: 9.1Level: LLTClassification code 10046859Term: Vaccination
EUCTR2009-011523-31-GBR & D, Cambridge University Hospitals60
Active, not recruiting
Phase 1
Response to Covid-19 vaccination in patients with cancerImmune response to Covid-19 vaccination of patients with immune modulatory treatment for cancerTherapeutic area: Body processes [G] - Immune system processes [G12]
EUCTR2021-000905-26-SEDepartment of Oncology, Uppsala University Hospita150
Active, not recruiting
Not Applicable
Etude des réponses immunitaires après vaccination anit-influenza saisonnier et anti-H1N1 variant pandémique dans une population de personnel soignant. - FLU-HOPsymptome de la grippeMedDRA version: 12.0Level: LLTClassification code 10016797Term: Flu-like symptoms
EUCTR2009-016267-11-FRInserm
Active, not recruiting
Phase 1
Immune response to COVID-19 Vaccination in people with Diabetes MellitusType 1 Diabetes MellitusType 2 Diabetes MellitusTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2021-001459-15-ATMedical University of Graz161
Active, not recruiting
Phase 1
Efficacité des immunoglobulines humaines normales (IGHN) dans les chocs toxiques (staphylococciques et streptococciques) : étude de faisabilité pédiatrique.toxic shock syndromeMedDRA version: 18.0Level: PTClassification code 10044248Term: Toxic shock syndromeSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2013-005509-29-FRHospices Civils de Lyon20